PUBLICATIONS

Hasan, S., Ahmed, M., Garcia-Ratés, S., Greenfield, S.A.. (2022) “Antagonising a novel toxin “T14” in Alzheimer’s disease: Comparison of receptor blocker versus antibody effects in vitro”. Biomedicine & Pharmacotherapy. 158 (2023) 114120 View PDF IF 7.4

Greenfield, S. A., Ferrati, G., Coen, C. W., Vadisiute, A., Molnár, Z., Garcia-Ratés, S., Frautschy, S., Cole, G. M.. (2022) “Characterization of a Bioactive Peptide T14 in the Human and Rodent Substantia Nigra: Implications for Neurodegenerative Disease“. International Journal of Molecular Sciences.  View PDF IF 6.2

Garcia-Ratés, S., Greenfield, S. A.. (2022) “When a trophic process turns toxic: Alzheimer’s disease as an aberrant recapitulation of a developmental mechanism“. International Journal of Biochemistry and Cell Biology. 149  106260. View PDF IF 5.6

Greenfield, S.A., Cole, G.M., Coen, C. W., Frautschy, S., Singh, R. P., Mekkittikul, M., Garcia-Ratés, S., Morrill, P., Hollings, O., Passmore, M., Hasan, S., Carty, N., Bison, S., Piccoli, L., Carletti, R., Tacconi, S., Chalidou, A., Pedercini, M., Kroecher, T., Astner, H., Gerrard, P. A. (2022). “A novel process driving Alzheimer’s disease validated in a mousemodel: Therapeutic potential”. Translational Research & Clinical Interventions. DOI: 10.1002/trc2.12274. View PDF IF 6.3

Ferrati, G., Bion, G., Harris, A.J.,Greenfield, S. A. (2019). “Protective and reversal actions of a novel peptidomimetic against a pivotal toxin implicated in Alzheimer’s diseas“. Biomed Pharmacoter. DOI:  10.1016/j.biopha.2018.10.124. View PDF IF 7.4

Ferrati, G., Brai, E., Stuart, S., Marino, C. and Greenfield, S. (2018). “A Multidisciplinary Approach Reveals an Age-Dependent Expression of a Novel Bioactive Peptide, Already Involved in Neurodegeneration, in the Postnatal Rat Forebrain“. Brain Sciences, 8(7), p.132. View PDF IF 3.17

Brai, E., Simon, F., Cogoni, A. and Greenfield, S. (2018). “Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer’s Disease”. Frontiers in Neuroscience, [online] 12. View PDF IF 4.5

Pepper, C, Tu, H, Morrill, P, Garcia-Rates, S, Fegan, C and Greenfield, S. (2017) “Tumour cell migration is inhibited by a novel therapeutic strategy antagonising the alpha-7 receptor.” Oncotarget. 2017 Feb 14;8(7):11414-11424. doi: 10.18632/oncotarget.14545. View PDF IF 3.3

Greenfield SA, Badin AS, Ferrati G, Devonshire IA. (2017) “Optical imaging of the rat brain suggests a previously missing link between top-down and bottom-up nervous system function.” Neurophoton. 4(3), 031213 (2017), doi: 10.1117/1.NPh.4.3.031213. View PDF IF 4.51

Garcia-Ratés, S and Greenfield SA (2017) “Cancer and neurodegeneration: two sides, same coin?” Oncotarget, 2017, Vol. 8, (No. 14), pp: 22307-22308 View PDF IF 3.3

Brai E, Stuart S, Badin AS & Greenfield SA. (2017) “A novel ex-vivo model to investigate the underlying mechanism in Alzheimer’s disease.” Front. Cell. Neurosci. Doi: 10.3389/fncel.2017.00291.View PDF 4.86

Badin, AS, Fermani, F and Greenfield, SA. (2017) “The features and functions of neuronal assemblies: possible dependency on mechanisms beyond synaptic transmission.” Front Neural Circuits. 2017 Jan 10;10:114. doi: 10.3389/fncir.2016.00114. eCollection 2016. View PDF IF 3.47

Garcia-Ratés, S, Morrill, P, Tu, H, Pottiez, G, Badin, A-S, Tormo-Garcia, C, Heffner, C, Coen, CW & Greenfield, SA. (2016) (I) “Pharmacological profiling of a novel modulator of the α7 nicotinic receptor: Blockade of a toxic acetylcholinesterase-derived peptide increased in Alzheimer brains.” Neuropharmacology, vol 105, pp. 487-499., 10.1016/j.neuropharm.2016.02.006. View PDF IF 5.25

Badin AS, Morrill P, Devonshire IM, Greenfield SA. (2016) (II) “Physiological profiling of an endogenous peptide in the basal forebrain: Age-related bioactivity and blockade with a novel modulator.” Neuropharmacology, 105:47-60. doi: 10.1016/j.neuropharm.2016.01.012. View PDF IF 5.25

Small GW, Greenfield S. “Current and Future Treatments for Alzheimer Disease.” Am J Geriatr Psychiatry. 2015 Nov; 23 (11):1101-5. doi: 10.1016/j.jagp.2015.08.006. View PDF

Greenfield SA (2013) “Discovering and targeting the basic mechanism of neurodegeneration: the role of peptides from the c-terminus of acetylcholinesterase Chemico-Biological Interactions“. 2013 May 25;203(3):543-6. doi: 10.1016/j.cbi.2013.03.015. Epub 2013 Apr 3. View PDF

Garcia-Ratés, S., Lewis, M., Worral R., & Greenfield S. A. (2013) “Additive Toxicity of β-Amyloid by aNovel Bioactive Peptide In Vitro: Possible Implications for Alzheimer’s Disease.” PLoS ONE 8(2):e54864. doi:10.1371/journal.pone.0054864 PLOS1. View PDF

Badin, S., Eraifej, J,. Greenfield, S. A. (2013) “High-resolution spatio-temporal bioactivity of a novel peptide revealed by optical imaging in rat orbitofrontal cortex in vitro: possible implications for neurodegenerative diseases”. Neuropharmacology. 2013 Oct;73:10-8. doi: 10.1016/j.neuropharm.2013.05.019. Epub 2013 May 24. View PDF

Halliday, A. C. & Greenfield, S. A. (2012) “From Protein to Peptides: a Spectrum of Non-Hydrolytic Functions of Acetylcholinesterase”. Protein & Peptide Letters 19, 165-172, doi:10.2174/092986612799080149. View PDF

Halliday, A. C., Kim, O., Bond, C. E. & Greenfield, S. A. (2010) “Evaluation of a technique to identify acetylcholinesterase C-terminal peptides in human serum samples”. Chem-Biol Interact 187, 110-114, doi:10.1016/j.cbi.2010.02.010. View PDF

Bond, C. E., Zimmermann, M. & Greenfield, S. A. (2009) “Upregulation of alpha 7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides.” Plos One 4, -, doi:Artn E4846 Doi 0.1371/Journal.Pone.0004846. View PDF

Zimmermann, M., Grosgen, S., Westwell, M. S. & Greenfield, S. A. (2008) “Selective enhancement of the activity of C-terminally truncated, but not intact, acetylcholinesterase.” J Neurochem 104, 221-232, doi:DOI 10.1111/j.1471-4159.2007.05045.x. View PDF

Greenfield, S. A., Zimmermann, M. & Bond, C. E. (2008) “Non-hydrolytic functions of acetylcholinesterase – The significance of C-terminal peptides.” Febs J 275, 604-611, doi:DOI 10.1111/j.1742-4658.2007.06235.x. View PDF

Bond, C. E. & Greenfield, S. A. (2007) “Multiple cascade effects of  oxidative stress on astroglia” Glia 55, 1348-1361, doi:Doi 10.1002/Glia.20547. View PDF

Onganer, P. U., Djamgoz, M. B. A., Whyte, K. & Greenfield, S. A. (2006) “An acetylcholinesterasederived peptide inhibits endocytic membrane activity in a human metastatic breast cancer cell line.” Bba-Gen Subjects 1760, 415-420, doi:DOI 10.1016/j.bbagen.2005.12.016. View PDF

Mann, E. O., Tominaga, T., Ichikawa, M. & Greenfield, S. A. (2005) “Cholinergic modulation of the spatiotemporal pattern of hippocampal activity in vitro.” Neuropharmacology 48, 118-133, doi:DOI 10.1016/j.neuropharm.2004.08.022.View PDF

Greenfield SA (2005) “A peptide derived from acetylcholinesterase is a pivotal signaling molecule in neurodegeneration.” Chemico-Biological Interactions Vol 157-158, pp 122-218. View PDF

Zbarsky, V., Thomas, J. & Greenfield, S. (2004) “Bioactivity of a peptide derived from acetylcholinesterase: involvement of an ivermectin-sensitive site on the alpha 7 nicotinic receptor.” Neurobiology of Disease 16, 283-289, doi:10.1016/j.nbd.2004.02.009. View PDF

Greenfield, S. A., Day, T., Mann, E. O. & Bermudez, I. (2004) “A novel peptide modulates alpha 7 nicotinic receptor responses: implications for a possible trophic-toxic mechanism within the brain“. J Neurochem 90, 325-331, doi:DOI 10.1111/j.1471-4159.2004.02494.x. View PDF

Emmett, S. R. & Greenfield, S. A. (2004) “A peptide derived from the C-terminal region of acetylcholinesterase modulates extracellular concentrations of acetylcholinesterase in the rat substantia nigra.” Neurosci Lett 358, 210-214, doi:DOI 10.1016/j.neulet.2003.12.078. View PDF

Day, T. & Greenfield, S. A. (2004) “Bioactivity of a peptide derived from acetylcholinesterase in hippocampal organotypic cultures”. Exp Brain Res 155, 500-508, doi:DOI 10.1007/s00221-003-1757-1. View PDF

Greenfield, S. A., Day, T., O.Mann, E., Bermundez, I. (2004) “A novel peptide modulates a7 nicotinic receptor responses: implications for a possible trophic-toxic mechanism within the brain”. Journal of Neurochemistry, 90, 325–331 doi:10.1111/j.1471-4159.2004.02494.x. View PDF

Emmett, S. R. & Greenfield, S.A. (2004) “A peptide derived from the C-terminal region of acetylcholinesterase modulates extracellular concentrations of acetylcholinesterase in the rat substantia nigra”. Neuroscience Letters, 358 (2004) 210–214. View PDF

Whyte, K. A. & Greenfield, S. A. (2003) “Effects of acetylcholinesterase and butyrylcholinesterase on cell survival, neurite outgrowth, and voltage-dependent calcium currents of embryonic ventral mesencephalic neurons.” Exp Neurol 184, 496-509, doi:Doi 10.1016/S0014-4886(03)00386-8. View PDF

Day, T. & Greenfield, S. A. (2003) “A peptide derived from acetylcholinesterase induces neuronal cell death: characterisation of possible mechanisms.” Exp Brain Res 153, 334-342, doi:DOI 10.1007/s00221-003-1567-5. View PDF

Bon, C. L. M. & Greenfield, S. A. (2003) “Bioactivity of a peptide derived from acetylcholinesterase: electrophysiological characterization in guinea-pig hippocampus.” Eur J Neurosci 17, 1991-1995, doi:DOI 10.1046/j.1460-9568.2003.02648.x. View PDF

Greenfield, S. & Vaux, D. J. (2002) “Parkinson’s disease, Alzheimer’s disease and motor neurone disease: Identifying a common mechanism.” Neuroscience 113, 485-492. View PDF

Day, T. & Greenfield, S. A. (2002) “A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: Molecular mechanisms.” Neuroscience 111, 649-656, doi:Pii S0306-4522(02)00031-3. View PDF